Loading
Latest filing published 23 Dec 2024 for IO Biotech, Inc., €9,700.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Mai-Britt Zocca in IO Biotech, Inc., where the filings describe the role as chief executive. We count 3 filings; the first trade dates from 9 November 2021 and the latest from 23 December 2024.
Every open-market trade on record is a purchase: 1 purchase worth €9,700, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. So far in 2024, the count stands at 1 purchase and no sales.
Most recently, on 23 December 2024, the filings show an open-market purchase worth €9,700 in IO Biotech, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations